IDEXX LaboratoriesFRA:IX1 -0.19%96 EBITDA Margin % is 35.14% as of Mar. 2026, which is 19% above its 10-year median of 29.64. GuruFocus rates FRA:IX1 with a GF Score™ of 96/100 and a GF Value™ of €552.99 (Modestly Undervalued). Among 204 Medical Diagnostics & Research companies, IDEXX Laboratories ranks better than 96.08% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. IDEXX Laboratories's EBITDA for the
three
months ended in Mar. 2026 was €347 Mil. IDEXX Laboratories's Revenue for the
three
months ended in Mar. 2026 was €987 Mil. Therefore, IDEXX Laboratories's EBITDA margin for the quarter that ended in Mar. 2026 was 35.14%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
IDEXX Laboratories EBITDA Margin % Related Terms
IDEXX Laboratories EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for IDEXX Laboratories's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:IX1 vs A, WAT, NTRA: EBITDA Margin % Comparison
For the Diagnostics & Research subindustry, IDEXX Laboratories's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IDEXX Laboratories EBITDA Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, IDEXX Laboratories's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where IDEXX Laboratories's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IDEXX Laboratories (FRA:IX1) has a EBITDA Margin % of 35.14% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on IDEXX Laboratories and its competitors. This is 19% above median its historical median of 29.64. Over the past decade, IDEXX Laboratories' EBITDA Margin % has ranged from 24.34 to 35.04. According to the industry distribution chart, IDEXX Laboratories ranks #8 out of 204 companies in the Medical Diagnostics & Research industry, placing it in the top 3.9%.
Is IDEXX Laboratories' EBITDA Margin % too high?
IDEXX Laboratories' current EBITDA Margin % of 35.14% is 19% above median its 10-year median of 29.64. Over the past 10 years, this metric has ranged from a low of 24.34 to a high of 35.04. The Medical Diagnostics & Research industry median EBITDA Margin % is 5.20. IDEXX Laboratories' value of 35.14% is 575.8% above this industry median. Based on the distribution chart, IDEXX Laboratories ranks #8 out of 204 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, IDEXX Laboratories has a GF Score™ of 96/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does IDEXX Laboratories' EBITDA Margin % compare to A and WAT?
According to the Medical Diagnostics & Research industry distribution chart, IDEXX Laboratories ranks #8 out of 204 companies for EBITDA Margin %. This places IDEXX Laboratories in the top 4% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 5.20. IDEXX Laboratories' value of 35.14% is 575.8% above this benchmark. Historically, IDEXX Laboratories' own EBITDA Margin % has ranged from 24.34 to 35.04 over the past decade. While the company's 10-year median is 29.64 vs. the industry median of 5.20, IDEXX Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Diagnostics & Research company?
The median EBITDA Margin % among Medical Diagnostics & Research companies is 5.20, based on 204 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. IDEXX Laboratories's current EBITDA Margin % of 35.14% is 575.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on IDEXX Laboratories and its competitors. For the Medical Diagnostics & Research industry, the median EBITDA Margin % is 5.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. IDEXX Laboratories's current EBITDA Margin % is 35.14%, which is 19% above median its own 10-year median of 29.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IDEXX Laboratories stock overvalued right now?
Based on GuruFocus' analysis, IDEXX Laboratories (FRA:IX1) is currently considered Modestly Undervalued. The stock's GF Value™ is €552.99, compared to a current price of €473.80 — trading 14.3% below its estimated fair value. The current EBITDA Margin % is 35.14%, which is 19% above median its 10-year median of 29.64 and 575.8% above the Medical Diagnostics & Research industry median of 5.20. IDEXX Laboratories' overall GF Score™ is 96/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For IDEXX Laboratories (FRA:IX1), the current EBITDA Margin % is 35.14% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is IDEXX Laboratories (FRA:IX1) Overvalued in 2026?
Based on GuruFocus' analysis, IDEXX Laboratories stock appears to be undervalued.
The current stock price of €473.80 is trading 14.3% below its estimated GF Value™ of €552.99.
GuruFocus considers IDEXX Laboratories to be Modestly Undervalued.
Key valuation signals for FRA:IX1:
EBITDA Margin %: 35.14% (19% above median its 10-year median of 29.64)
GF Value™: €552.99 vs. price of €473.80 (14.3% below fair value)
Industry Position: 575.8% above the Medical Diagnostics & Research median (#8 of 204)
No single metric tells the full story. See the FRA:IX1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx derives roughly 35% of its revenue from outside the United States.
96GF Score
Get the complete analysis for FRA:IX1
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:IX1 has been successfully added to your 
